[
    [
        {
            "time": "",
            "original_text": "泰格医药：2017年净利润同比增116.91%（快报）",
            "features": {
                "keywords": [
                    "泰格医药",
                    "净利润",
                    "同比增长",
                    "116.91%",
                    "快报"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药：2017年净利润同比增116.91%（快报）",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "泰格医药股票怎么样：业绩高速增长，受益于创新药行业发展",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩",
                    "高速增长",
                    "创新药",
                    "行业发展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药股票怎么样：业绩高速增长，受益于创新药行业发展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "【川财研究*医药生物】泰格医药（300347）：2017业绩高增长，长期坚定看好",
            "features": {
                "keywords": [
                    "川财研究",
                    "医药生物",
                    "泰格医药",
                    "2017",
                    "业绩高增长",
                    "长期看好"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【川财研究*医药生物】泰格医药（300347）：2017业绩高增长，长期坚定看好",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "泰格医药:年报业绩符合预期,鼓励创新药和仿制药一致性评价政策双受益",
            "features": {
                "keywords": [
                    "泰格医药",
                    "年报",
                    "业绩",
                    "符合预期",
                    "创新药",
                    "仿制药",
                    "一致性评价",
                    "政策",
                    "双受益"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药:年报业绩符合预期,鼓励创新药和仿制药一致性评价政策双受益",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]